{"entity":{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","aka":["ArriVent BioPharma, Inc.","ArriVent"],"tldr":"ArriVent is a Pennsylvania company developing furmonertinib, an EGFR inhibitor approved in China, for EGFR exon 20 insertion and other uncommon EGFR-mutant lung cancers in global trials.","summary":"ArriVent BioPharma, based in Newtown Square, Pennsylvania and listed on Nasdaq since 2024, licenses medicines approved in China for development elsewhere. Its lead is furmonertinib (firmonertinib), a third-generation EGFR inhibitor from Allist Pharmaceuticals that is approved in China for EGFR-mutant non-small-cell lung cancer; ArriVent runs the global phase 3 FURVENT trial in EGFR exon 20 insertion mutations, where it holds FDA breakthrough designation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.arrivent.com"},{"label":"ClinicalTrials.gov: trials led by ArriVent BioPharma","url":"https://clinicaltrials.gov/search?lead=ArriVent%20BioPharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":["egfr"],"drugs":["furmonertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Newtown Square, PA","country":"US","companyType":"biotech","website":"https://www.arrivent.com","stage":"public","investors":[],"funding":[]},"route":"/companies/arrivent/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"}]}}